News &amp; Updates

The investigational JAK1* inhibitor filgotinib was noninferior to adalimumab in reducing disease activity in patients with moderate-to-severe rheumatoid arthritis (RA) who had inadequate response to methotrexate (MTX-IR), according to the FINCH 1 study presented at EULAR 2020 Virtual Meeting.

Novel JAK1 inhibitor on par with adalimumab in RA over 52 weeks

SELECT-PsA-1 demos upadacitinib benefits in psoriatic arthritis

Upadacitinib may be a suitable treatment for patients with active psoriatic arthritis (PsA) who have insufficient response to non-biologic disease-modifying anti-rheumatic drugs (non-bDMARDs), according to results of the phase III SELECT-PsA-1* trial presented at EULAR 2020.

SELECT-PsA-1 demos upadacitinib benefits in psoriatic arthritis

OnabotulinumtoxinA effectively controls chronic migraine

Long-term use of onabotulinumtoxinA led to reductions in monthly headache days (MHDs) in adults with chronic migraine (CM), according to post hoc analyses of the COMPEL* study presented at the AHS 2020 virtual scientific meeting.

OnabotulinumtoxinA effectively controls chronic migraine

Is ticagrelor protective against osteoarthritis too?

Ticagrelor reduces the risk of developing osteoarthritis by about 30 percent compared with another antiplatelet, clopidogrel, as shown in a recent study.

Is ticagrelor protective against osteoarthritis too?

Apremilast improves oral ulcers in patients with Behçet’s syndrome

Treatment with apremilast, an oral phosphodiesterase 4 inhibitor, significantly reduced the number of oral ulcers in patients with Behcet’s syndrome, according to the RELIEF* study presented at EULAR 2020.

Apremilast improves oral ulcers in patients with Behçet’s syndrome

An aspirin a day keeps colorectal cancer at bay?

Taking 600 mg aspirin daily significantly reduces the risk of colon cancer over 10 years in people with Lynch syndrome — which genetically predisposes them to colon cancer, the CAPP*2 study shows.

An aspirin a day keeps colorectal cancer at bay?

Letrozole a promising alternative for managing ectopic pregnancy

The aromatase inhibitor letrozole has demonstrated success in the treatment of women with ectopic pregnancy, with encouragingly high resolution rate and having a better safety profile relative to the chemotherapeutic agent methotrexate, according to a pilot trial.

Letrozole a promising alternative for managing ectopic pregnancy

Ursodeoxycholic acid may prevent post-gastrectomy gallstones in gastric cancer

A daily dose of ursodeoxycholic acid (UDCA) may prevent gallstone formation in patients with gastric cancer who have undergone gastrectomy, suggested results of the PEGASUS-D trial.

Ursodeoxycholic acid may prevent post-gastrectomy gallstones in gastric cancer

Dorzagliatin SEEDs good outcomes in T2D

The novel dual-acting glucokinase activator (GKA) dorzagliatin provides good glycaemic control and has a favourable safety profile in Chinese patients with type 2 diabetes (T2D), the phase III SEED* study has shown.

Dorzagliatin SEEDs good outcomes in T2D

Do common BP-lowering drugs shield users against viral infections?

Treatment with either angiotensin receptor blockers (ARBs) or angiotensin-converting-enzyme inhibitors (ACEIs) not only help control blood pressure (BP) in hypertensive patients but may also confer protection against viral infections, a study has found.

Do common BP-lowering drugs shield users against viral infections?